CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
2.870
+0.110 (3.99%)
At close: Aug 7, 2026, 4:00 PM EDT
2.850
-0.020 (-0.70%)
After-hours: Aug 7, 2026, 7:46 PM EDT
CervoMed Employees
CervoMed had 15 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
15
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$22,086
Profits / Employee
-$2,023,316
Market Cap
38.82M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15 | 0 | - |
| Dec 31, 2024 | 15 | 7 | 87.50% |
| Dec 31, 2023 | 8 | 4 | 100.00% |
| Mar 31, 2023 | 4 | - | - |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BeyondSpring | 44 |
| PDS Biotechnology | 21 |
| Veru Inc. | 20 |
| Lantern Pharma | 16 |
| Serina Therapeutics | 16 |
| Apollomics | 14 |
| Nutriband | 13 |
| Hyperion DeFi | 9 |
CRVO News
- 2 days ago - CervoMed Quarterly report: Q2 2026 - Filings
- 4 days ago - CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference - GlobeNewsWire
- 5 days ago - CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB) - GlobeNewsWire
- 26 days ago - CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) - GlobeNewsWire
- 4 weeks ago - CervoMed completes enrollment in neflamapimod study - TheFly
- 4 weeks ago - CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia - GlobeNewsWire
- 4 weeks ago - CervoMed registers to sell 10.08M shares of common stock for holders - TheFly
- 4 weeks ago - CervoMed Registration statement: Registration filing - Filings